From ground-breaking research to revolutionary prognostics and diagnostics
AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies.
These new prognostic tests will better identify a patient’s true risk of disease progression, so that individuals can be counselled and treated appropriately, and precious healthcare resources can be targeted effectively to the patients who need it most.
AMLo Biosciences is currently working on prognostic products for three cancers where clinicians have a significant need for better information to enable them to treat patients more effectively.
Melanoma, a type of skin cancer, is the 5th most common cancer in the UK and the US.[1,2]
Australia and New Zealand have the highest rates of melanoma in the world, while the US and much of Europe rank in the top 20 countries in terms of melanoma prevalence. Globally, there were more than 320,000 new cases of melanoma in 2020 and more than 57,000 deaths from this cancer.
Oropharyngeal squamous cell carcinoma (OPSCC)
OPSCC represents one quarter of the total head and neck cancers diagnosed, causing approximately 97,000 deaths per year worldwide. Incidence is steadily increasing year on year, with an estimated 173,495 new cases in 2018 and with the highest incidence occurring in Western countries.
AMLo Biosciences: A team of internationally acclaimed experts with a common goal
AMLo Biosciences Limited is a private limited company registered in England and Wales. The company was founded in 2017 by a team with an internationally acclaimed track record in the oncology field, spanning the identification of translational biomarkers, drug discovery and development. A team who also has experience in building successful biotech companies.
In the past few years, projects associated with the development of our melanoma prognostic test, AMBLor®, have attracted nearly £2 million in research funding and £2.4 million in equity funding.
Improving health economics
The total annual cost due to skin cancer to the NHS was £112 million in 2008 and is predicted to reach over £338 million by 2025.[10,11] In the US, the annual expenditure on skin cancer is $8.1 billion.
The COVID-19 pandemic has put even more strain on healthcare systems, including an unprecedented burden of delayed cancer presentations. In the COVID-19 period, there was a decrease in skin cancer diagnoses of 67% in the UK. At present, even patients with early-stage melanoma, which comprise >90% of all melanomas, are treated as if they are at risk of the disease spreading. In reality, fewer than 15% will suffer disease progression.[14,15] AMLo’s test will enable risk stratification of individual melanomas leading to more appropriate follow-up for patients at low risk of disease progression and consequent cost savings.
With considerable annual spending by worldwide health economies on skin cancer care, we believe efficiencies can be achieved by better stratification of personal risk of melanoma progression.
The test AMLo is exclusively developing will be simple to use and fit seamlessly into current diagnostic practice. Find out more here.
Delivering health impact
The incidence of melanoma skin cancer has reached epidemic proportions. Global cases will reach nearly half a million by 2040, an increase of 62% on 2018 figures. The time to improve care and optimise the use of precious healthcare resources is now.
Improving prognostics in melanoma has the potential to transform standard of care. It will enable those patients with melanomas that are genuinely at low-risk of disease progression to be given reassurance and better-informed follow up care, while those identified to be at-risk of progression will receive timely treatment and standard-of-care follow up.
AMLo Biosciences plans to launch its technology globally and make a positive impact on the lives of the 300,000+ people diagnosed worldwide with malignant melanoma every year.
A ground-breaking explanation of the mechanism by which early-stage melanomas become at risk of spreading has just been published in the British Journal of Dermatology. The team at Newcastle University, led by Professor Penny Lovat, in association with AMLo...
Increasing evidence for the application of FAK inhibitors in melanoma therapy Presented at the Society for Melanoma Research (SMR) Virtual Congress, October 2021 AMLo’s Chief Scientific Officer, Professor Penny Lovat, participated in the research that is presented in...
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address: Office 9, The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne, NE4 5BX
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter